We are live on
!
Find out more
PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$4.89B
1-Year Est. Return
251.12%
This Fund
S&P 500
This Quarter
Est. Return
-1.92%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.61B
AUM Growth
-$228M
(-8%)
Cap. Flow
-$39.5M
Cap. Flow
% of AUM
-1.51%
Top 10 Holdings %
Top 10 Hldgs %
64.57%
Holding
44
New
10
Increased
10
Reduced
11
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRUS
Merus
MRUS
|
+$97.8M |
| 2 |
Revolution Medicines
RVMD
|
+$87.6M |
| 3 |
Janux Therapeutics
JANX
|
+$73.5M |
| 4 |
BridgeBio Pharma
BBIO
|
+$29.8M |
| 5 |
Kura Oncology
KURA
|
+$28.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Immunocore
IMCR
|
+$116M |
| 2 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$84.1M |
| 3 |
BCYC
Bicycle Therapeutics
BCYC
|
+$80.8M |
| 4 |
Vaxcyte
PCVX
|
+$41.7M |
| 5 |
AUTL
Autolus Therapeutics
AUTL
|
+$41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cullinan Oncology
CGEM
$1.01B
| $26.9M | 1.03% |
1,542,805
+194,790
| +14% | +$4.15M |
|
27
Erasca
ERAS
$6.3B
| $17.1M | 0.65% |
+7,250,000
| New | +$15.6M |
|
|
CMPS
28
Compass Pathways
CMPS
$1.53B
| $14.1M | 0.54% |
2,335,926
-55,062
| -2% | -$433K |
|
29
Apogee Therapeutics
APGE
$10.1B
| $13M | 0.5% |
330,000
| – | – |
|
|
VRNA
30
DELISTED
Verona Pharma
VRNA
| $10.4M | 0.4% |
+721,087
| New | +$10.5M |
|
31
ALX Oncology
ALXO
$261M
| $9.5M | 0.36% |
+1,575,605
| New | +$19.4M |
|
32
Perspective Therapeutics
CATX
$332M
| $9.17M | 0.35% |
+919,692
| New | +$13.3M |
|
33
Vor Biopharma
VOR
$1.15B
| $6.46M | 0.25% |
322,865
| – | – |
|
34
Acrivon Therapeutics
ACRV
$64.2M
| $3.83M | 0.15% |
+659,724
| New | +$5.31M |
|
35
TScan Therapeutics
TCRX
$48.6M
| $2.07M | 0.08% |
+353,886
| New | +$2.79M |
|
36
Agios Pharmaceuticals
AGIO
$1.79B
| – | – |
-400,000
| Closed | -$11.7M |
|
|
AUTL
37
Autolus Therapeutics
AUTL
$397M
| – | – |
-6,425,803
| Closed | -$41M |
|
|
BCYC
38
Bicycle Therapeutics
BCYC
$269M
| – | – |
-3,246,759
| Closed | -$80.8M |
|
39
Caribou Biosciences
CRBU
$145M
| – | – |
-2,172,620
| Closed | -$11.2M |
|
|
CRGX
40
DELISTED
CARGO Therapeutics
CRGX
| – | – |
-147,959
| Closed | -$3.3M |
|
|
41
Immunocore
IMCR
$1.72B
| – | – |
-1,787,176
| Closed | -$116M |
|
42
Zentalis Pharmaceuticals
ZNTL
$337M
| – | – |
-944,917
| Closed | -$14.9M |
|
43
Kyverna Therapeutics
KYTX
$444M
| – | – |
-50,000
| Closed | -$1.24M |
|
|
ALPN
44
DELISTED
Alpine Immune Sciences Inc
ALPN
| – | – |
-2,121,163
| Closed | -$84.1M |
|
Similar funds
KCM
DGI
FC
MCM
MCCA
SIA
SCA
SMFG
Paradigm Biocapital Advisors's Q2 2024 Portfolio in Review
As of Q2 2024, Paradigm Biocapital Advisors held 44 positions worth $2.61B, down 8% from $2.84B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Paradigm Biocapital Advisors's Q2 2024 filing shows 10 new, 10 increased, 11 reduced and 9 closed positions. Its largest new stake was Merus: 2,019,814 shares worth $120M. The largest sale was Immunocore, an estimated $116M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Paradigm Biocapital Advisors's largest Q2 2024 buy was Merus: 2,019,814 shares worth $120M.
- Paradigm Biocapital Advisors added most to Revolution Medicines in Q2 2024, an estimated $87.6M increase.
- Paradigm Biocapital Advisors's biggest Q2 2024 reduction was Vaxcyte, cutting an estimated $41.7M.
- Paradigm Biocapital Advisors fully exited Immunocore in Q2 2024, selling an estimated $116M.
- Paradigm Biocapital Advisors's ten largest holdings make up 65% of its $2.61B portfolio in Q2 2024.
- Paradigm Biocapital Advisors opened 10 new positions and closed 9 in Q2 2024.
- Paradigm Biocapital Advisors's portfolio value fell 8% quarter-over-quarter to $2.61B.
Based on Paradigm Biocapital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.